company background image
0QNO logo

Lonza Group LSE:0QNO Stock Report

Last Price

CHF 604.10

Market Cap

CHF 43.6b

7D

3.7%

1Y

35.2%

Updated

07 Feb, 2025

Data

Company Financials +

Lonza Group AG

LSE:0QNO Stock Report

Market Cap: CHF 43.6b

0QNO Stock Overview

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details

0QNO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 21.1% per year

Risk Analysis

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

Lonza Group AG Competitors

GSK

LSE:GSK

UK£58.9b

hVIVO

AIM:HVO

UK£119.1m

AstraZeneca

LSE:AZN

UK£179.9b

Agilent Technologies

NYSE:A

US$42.2b

Price History & Performance

Summary of share price highs, lows and changes for Lonza Group
Historical stock prices
Current Share PriceCHF 604.10
52 Week HighCHF 615.80
52 Week LowCHF 438.25
Beta0.67
1 Month Change8.47%
3 Month Change10.18%
1 Year Change35.20%
3 Year Change-1.63%
5 Year Change44.90%
Change since IPO611.63%

Recent News & Updates

Recent updates

Shareholder Returns

0QNOGB Life SciencesGB Market
7D3.7%-6.4%1.0%
1Y35.2%-21.2%12.1%

Return vs Industry: 0QNO exceeded the UK Life Sciences industry which returned -21.2% over the past year.

Return vs Market: 0QNO exceeded the UK Market which returned 12.1% over the past year.

Price Volatility

Is 0QNO's price volatile compared to industry and market?
0QNO volatility
0QNO Average Weekly Movement3.9%
Life Sciences Industry Average Movement8.3%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0QNO has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QNO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
189718,686Wolfgang Wienandwww.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.

Lonza Group AG Fundamentals Summary

How do Lonza Group's earnings and revenue compare to its market cap?
0QNO fundamental statistics
Market capCHF 43.61b
Earnings (TTM)CHF 636.00m
Revenue (TTM)CHF 6.57b

68.6x

P/E Ratio

6.6x

P/S Ratio

Is 0QNO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QNO income statement (TTM)
RevenueCHF 6.57b
Cost of RevenueCHF 4.16b
Gross ProfitCHF 2.41b
Other ExpensesCHF 1.78b
EarningsCHF 636.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 03, 2025

Earnings per share (EPS)8.81
Gross Margin36.67%
Net Profit Margin9.67%
Debt/Equity Ratio50.2%

How did 0QNO perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

45%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 22:40
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lonza Group AG is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Volker BosseBaader Helvea Equity Research
Charles Pitman-KingBarclays